Bioequivalency, Insulin and Marketing - Clinical Research Informer

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

FEBRUARY 8, 2021

As biologics have the reputation of being expensive due to their complex nature and production, biosimilars have the ability to improve market access to patients and payors who would otherwise be unable to afford these drugs. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed.

Production

Production Insulin Branding Generic Drugs

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

The Pharma Data

DECEMBER 28, 2020

Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. billion, three biosimilar products in development targeting products with a market size of approximately $13.0

Bioequivalency

Bioequivalency Production Sales Marketing

Clinical Research Informer

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

Webinars

Stay Connected